You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
復星醫藥(02196.HK):HLX1一線治療不可切除的晚期肝細胞癌(HCC)患者於中國境內啟動 I/III 期臨牀試驗
格隆匯 05-16 17:16

格隆匯5月16日丨復星醫藥(02196.HK)公佈,近日,公司控股子公司上海復宏漢霖生物技術股份有限公司及其控股子公司自主研發的伊匹木單抗生物類似藥 HLX13(重組抗 CTLA-4 全人單克隆抗體注射液,以下簡稱"HLX13")一線治療不可切除的晚期肝細胞癌(HCC)患者於中國境內啟動 I/III 期臨牀試驗。

HLX13 為集團(即公司及控股子公司/單位,下同)自主研發的伊匹木單抗生物類似藥,擬用於治療黑色素瘤、腎細胞癌、結直腸癌、肝細胞癌、非小細胞肺癌、惡性胸膜間皮瘤及食管鱗狀細胞癌。截至 2025 年 4 月,本集團現階段針對 HLX13 累計研發投入約為人民幣 1.04 億元(未經審計)。

根據 IQVIA MIDASTM最新數據1,2024 年,伊匹木單抗製劑於全球範圍內的銷售額約為 28.73 億美元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account